Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Asset Writedowns and Impairment (2016 - 2018)

Lisata Therapeutics (LSTA) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with -$1.4 million as the latest value for Q2 2018.

  • For the quarter ending Q2 2018, Asset Writedowns and Impairment fell 1173.03% year-over-year to -$1.4 million, compared with a TTM value of -$1.3 million through Jun 2018, down 200.9%, and an annual FY2015 reading of $62.3 million, changed N/A over the prior year.
  • Asset Writedowns and Impairment was -$1.4 million for Q2 2018 at Lisata Therapeutics, down from $128492.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $52.9 million in Q4 2015 and bottomed at -$1.4 million in Q2 2018.
  • Average Asset Writedowns and Impairment over 4 years is $8.7 million, with a median of $128492.0 recorded in 2017.
  • The sharpest move saw Asset Writedowns and Impairment plummeted 92.0% in 2017, then plummeted 1173.03% in 2018.
  • Year by year, Asset Writedowns and Impairment stood at $52.9 million in 2015, then plummeted by 101.12% to -$591307.0 in 2016, then soared by 121.73% to $128492.0 in 2017, then tumbled by 1173.03% to -$1.4 million in 2018.
  • Business Quant data shows Asset Writedowns and Impairment for LSTA at -$1.4 million in Q2 2018, $128492.0 in Q2 2017, and $47301.0 in Q1 2017.